glp-1-based treatments approved for weight loss 2025 Weight-loss drugs such as Ozempic were in the headlines a lot in – and patent protections these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ The FDA has approved the

GLP-1 drugs (glucagon-like peptide-1 receptor agonists) are medications developed to treat both type 2 diabetes and obesity by correcting hormonal imbalance - stimulating insulin release and suppressing excess glucagon -to bring blood sugar back under control

Shivappa N, Swift C, Noone J, Du S, Radin M, Gamble C

doi:10.1016/j.phrs.2023.107031 192

Blocking PINK1/Parkin-dependent mitophagy sensitizes multidrug-resistant liver cancer cells to B5G1, a new derivative of betulinic acid [319]

The evidence presented in this article derives from observational studies, retrospective cohort analyses, and emerging preclinical research